🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Specific binding to cell surface glycans is the basis for diagnostic and therapeutic applications in the area of cancer and infectious disease. Happy to report a breakthrough in #glycotime projects on Generation of glycan-specific nanobodies sciencedirect.com/science/articl…

Congratulations 🎈🎊🍾🎉 Lara

Impressive study on regulation of mucin secretion from Kelly Ten Hagen's lab Regulated Restructuring of Mucins During Secretory Granule Maturation In Vivo | Proceedings of the National Academy of Sciences pnas.org/doi/10.1073/pn…

If you are curious about site-specific O-glycans in human tissue formation, check out our comprehensive study defining mucin patches O-glycan occupancy, and contributions from individual GalNAc-Ts. #glycotime #massspectrometry #glycomics nature.com/articles/s4146…

Have a look at our cover story at Science Signaling where Zilu Ye et al. use 3D tissue models, CRISPR, and (phospho)proteomics to define TGF-β signaling during skin formation and invasive cancer growth. Great collab with Sally, JesperOlsenLab, and Cord Silverstein Brakebusch.

Leveraging #proteomics and a 3D model of human skin, researchers probe the role of #TGFBeta in normal #SkinBiology and show that loss of the receptor TGF-beta-RII induces the spread of invasive skin tissue. Zilu Ye Hans Wandall Jesper V. Olsen Copenhagen Center for Glycomics scim.ag/Dt

A fantastic sunny day last week when Asha Rudjord-Levann defended her Ph.D. thesis on glycosaminoglycans in skin biology. Huge congratulations, and thank you to Göran Larson, Cathy Merry, and Héctor Herranz for being such great opponents!

Dysregulated Zn2+ as a cause of truncated O-glycans in cancer? Look at our CRISPR screen identifying ZIP9 regulating glycosylation. Could explain some of the Tn/STn in cancers (see Rømer and Aasted et al. Br. J. Cancer, 2021). academic.oup.com/glycob/advance…

A few years ago, we founded Ebumab and spun out Hemab devoted to treating rare bleeding disorders. The Hemab leadership has now secured $135 million in Series B financing for future growth. Impressive! hemab.com

Galectin-1 a targetable checkpoint in human cancers? Here we show that Galectin-1 induces tumor-associated like macrophages with increased expression of IDO1 and PD-L1 in human cancers. sciencedirect.com/science/articl…

Serieiværksætter henter første store bevilling til nyt kræftfirma medwatch.dk/Medicinal___Bi…

glyco-CARTs for the treatment of solid cancers! See our new publication, where we use a mAb with exquisite cancer-specificity to target cancer-associated O-glycans on CD44v6 expressed on multiple solid tumors. aacrjournals.org/mct/article/do…

Great fun at Culture Night 2023 at the University of Copenhagen playing with Lego and telling glyco-tales. Thanks to Tommy Jaroentomeechai, Janneke Elzinga, Zofia Karolina Szulc, Felix Goerdeler, Kasper Budolph Pedersen, Katarina Madunic, Sally Dabelsteen and Fredrik Wandall.

I am thrilled to share our paper on the roles of glycans in HSV-1 infection of skin cells out Nature Communications today. It is dear to my heart having worked on it with the best buddies Copenhagen Center for Glycomics and with help from our friends in Sweden. rdcu.be/dp5gE Hans Wandall #glycotime

Thank you to the organizers for this year's excellent  2023 Society for Glycobiology Meeting on Transformative Advances in the Biological Functions of Glycans in Hawaii. I enjoyed all the good talks and seeing friends.  #SFG2023, #glycotime

Check out the new publication in nature commun from Ieva Bagdonaite on how Herpes Virus exploits glycans to infect. Excellent collaboration with Sally Dabelsteen, Sigvard Olofsson, Rickard Nordén, and Tomas Bergström. #glycotime rdcu.be/dqS6u

Ph.D. positions are available at the Wandall group at the University of Copenhagen. Positions are part of the MSCA Doctoral Network TOP-GUT on gastro-intestinal models for advancing personalized medicine. Positions start in March 2024 or later. lnkd.in/d4T9RVE8

Copenhagen Center for Glycocalyx is looking for talented Postdocs to work in cell biology, glycobiology, genetic engineering, and mass spectrometry. Do not hesitate to reach out! Find details at: lnkd.in/eyhWJQgv and lnkd.in/eKjmiCuCare

We need to expand treatment options for more cancer patients! Excited to help drive innovation in cancer care with GO’s advanced glycopeptide platform, delivering next-gen clean targets to ADCs, CAR Ts, and bispecifics. pharma.h5mag.com/pharma_sep24/e…

At #AACR2025 we are presenting GO-Therapeutics’ glyco-platform: converts classic targets into tumor-specific mAbs. Lead ADC R800-vedotin delivers sub-nM affinity & potent PDx efficacy - sparing healthy tissue. Poster 9 AM, Sec 34/2131. #Oncology #ADC #Glycobiology